News related to
Meta

Private firms are allocating an average of 22 per cent of their profits into Bitcoin, as revealed by a new analysis from River, a specialist in Bitcoin financial services. The move underscores an accelerating wave of adoption from traditional companies across sectors from real estate to hospitality, driven by favourable regulation, strengthened accounting clarity, and a buoyant bull market.

River’s data shows that real estate businesses are leading this charge, with nearly 15 per cent reinvesting profits into Bitcoin, while hospitality, finance, and software firms direct between 8 per cent and 10 per cent. Even smaller, diverse businesses—including fitness studios, painting outfits, roofing contractors, and religious nonprofits—are joining the trend. By 2025, these private firms have quietly amassed 84,000 bitcoins, amounting to roughly a quarter of what institutional fund managers and corporate treasury holders combined have acquired.

The underlying conditions for this surge are clear. River attributes the shift to improved Bitcoin accounting standards, regulatory certainty, growing institutional acceptance, and a strong bull market that has seen Bitcoin’s value surge—creating an “ideal environment for widespread adoption”.

Smaller businesses, typically with fewer than 50 employees, account for 75 per cent of River’s clients, and appear to find Bitcoin adoption simpler than larger corporations. Those with complex, committee-based governance are more cautious, often awaiting peer precedent before committing—even when convinced of Bitcoin’s long-term value.

Adoption patterns also vary in scale. Over 40 per cent of the businesses allocate between 1 per cent and 10 per cent of profits to Bitcoin, while just 10 per cent invest more than half of their net income into the cryptocurrency.

This wave of grassroots participation complements broader institutional demand. River reports that public and private firms—the latter including treasury-managed corporations—are purchasing approximately 1,755 BTC per day on average in 2025. Exchange-traded funds and other investment vehicles are acquiring about 1,430 BTC per day, and governments add another 39 BTC daily. These figures stack up sharply against miner output, which is only around 450 BTC per day—raising the likelihood of a supply squeeze if exchange inventories continue to deplete.

Institution-grade buyers are also piling in. Bitcoin treasury firms accounted for 159,107 BTC acquired in the second quarter of 2025, pushing the total corporate and business-held Bitcoin to around 1.3 million BTC. Michael Saylor’s company Strategy remains the dominant corporate holder, with more than 630,000 BTC under its control.

Parallel developments illustrate the growing strategic shift toward Bitcoin within corporate finance. In the United States, investor Anthony Pompliano orchestrated a $1 billion SPAC merger to launch ProCap Financial, a new Bitcoin treasury firm with an ambition to manage up to $1 billion in cryptocurrency holdings. The firm plans to monetise its holdings through lending, derivatives, and other services, pushing the boundaries of Bitcoin treasury strategies.

Across the Atlantic, UK markets are witnessing their own momentum. At least nine London-listed companies—from technology to mining ventures—have either acquired Bitcoin or announced plans to do so, seeking similar boosts in investor appeal. Despite historical resistance from regulators concerned about money‑laundering risks, the Financial Conduct Authority appears open to easing restrictions, offering a potential regulatory tailwind to adoption in Britain.

This widespread movement mirrors and builds upon earlier corporate Bitcoin trends. As of mid‑2025, nearly 130 publicly traded companies held about $87 billion in Bitcoin, or 3.2 per cent of the total supply, driven by the ‘Bitcoin treasury’ blueprint pioneered by Strategy. Firms including Tesla, Metaplanet, Twenty One Capital, Block, GameStop, and Trump Media & Technology Group have followed suit, deploying equity issuance, bonds, and convertible debt to fund their Bitcoin accumulation.

Analysts also project an enormous potential inflow of corporate capital: Bernstein Research estimates that corporate demand could funnel as much as $330 billion into Bitcoin by 2029, with up to $124 billion attributable to Strategy alone.

Anthropic has secured a monumental US $13 billion Series F funding round, propelling its post-money valuation to approximately US $183 billion and firmly establishing itself as one of the highest valued private startups globally. The round was spearheaded by Iconiq Capital, Fidelity Management & Research, and Lightspeed Venture Partners, with the Qatar Investment Authority joining as a “significant” investor alongside an impressive roster of global financial institutions and sovereign wealth funds.

Anthropic’s valuing nearly tripled since March, climbing from US $61.5 billion, when it completed a US $3.5 billion Series E raise earlier in 2025. This leap reflects the surging investor appetite for generative AI developers, despite growing debates over tech spending sustainability.

Anthropic’s growth trajectory is underpinned by its financial performance. The company’s run-rate revenue soared from roughly US $1 billion at the start of 2025 to over US $5 billion by August. The enterprise customer base now tops 300,000, with so-called “large accounts” expanding nearly seven-fold in just one year.

The rise of Claude Code, Anthropic’s developer-centric AI tool launched fully in May 2025, has been especially impactful. It currently generates over US $500 million in run-rate revenue, and usage has surged more than ten-fold within three months.

Anthropic’s research credentials and product roadmap also underpin its valuation. In August, the company rolled out Opus 4.1, an upgrade tailored to agentic tasks, coding, and reasoning. Its rapid expansion, focus on AI safety, and growing international footprint were cited by investors as further proof of its potential.

The participation of the Qatar Investment Authority marks a notable chapter in Gulf sovereign wealth funds’ deepening role in AI financing. While Anthropic did not disclose the precise QIA investment amount, it was highlighted as a “significant” backer in the funding syndicate. QIA’s April 2025 holdings were estimated at around US $557 billion, underscoring the strategic weight that such sovereign investments carry in global tech markets.

This infusion of capital will enable Anthropic to scale its enterprise operations, intensify its AI safety research, and accelerate international growth of its Claude platform. Amazon, already a stakeholder, may deploy the funding to expand its cloud infrastructure support for Anthropic, particularly through AWS Project Rainier. Analysts note this could meaningfully boost Anthropic’s spending on cloud services, with projections suggesting an uptick to as much as US $5 billion by 2026.

Amid this whirlwind of funding and growth, some experts caution about the long-term sustainability of such capital-intensive AI ventures. Infrastructure demands for large language model development can rival those of tech giants like Google, Microsoft, or Meta.

Etihad Airways has stressed it has no set timetable for a public listing, affirming that its $20 billion expansion over the coming decade can be financed from within.

The airline’s chief executive, Antonoaldo Neves, confirmed it is prepared for an initial public offering, yet the decision remains with its shareholder—Abu Dhabi’s sovereign wealth fund, ADQ. He stated that “the time has not come yet”, emphasising that Etihad can self‑fund its next phase of growth.

Neves traced the shift in strategy to ADQ’s acquisition of Etihad in October 2022, which ushered in a focus on organic growth and strengthened regional connectivity through Abu Dhabi, rather than continuing merger or acquisition activity.

Passenger demand continues to rise, with traffic up 17 percent year‑on‑year and load factors climbing to 88 percent—up from 86 percent a year earlier. Despite a slowdown during the Israel-Iran conflict, bookings rebounded fully by the end of July, demonstrating robust consumer interest.

Etihad’s fleet exceeds 100 aircraft, spanning both Airbus and Boeing models. In May, the airline placed a major order with Boeing for 28 wide‑body jets—including 777X aircraft destined to replace its Airbus A380s after 2030. Neves also revealed plans to supplement fleet expansion via secondhand aircraft and lessor sourcing.

This public statement builds upon a broader narrative unfolding over the past year. Etihad reported profitability in 2022 and 2023—92 million dirhams and 525 million dirhams respectively—after years of losses. The airline has been enhancing transparency, governance, and operational efficiency, eliminating underperforming routes and returning grounded aircraft to service.

Earlier projections had flagged a possible IPO no earlier than 2025, allowing Etihad to bolster its financials before a listing. Speculative growth targets under its “Journey 2030” strategy include expanding to over 125 destinations and substantially growing its fleet.

Other commentary from February 2025 suggested Neves intended to float a stake of up to 20 percent on the Abu Dhabi stock exchange, possibly valuing the airline at $5 billion, and underscored his readiness for a float—though final approval again resides with ADQ.

Throughout this period, Etihad has forged strategic alliances. A landmark joint venture with China Eastern Airlines will coordinate schedules and revenues on selected routes from 2025, the first such pact between Middle East and Chinese carriers. Additionally, the airline has broadened its network through expanded service offerings to emerging and mid‑distance markets, positioning Abu Dhabi as a strategic travel hub.

A team led by Khalil Ramadi at NYU Tandon and NYU Abu Dhabi has unveiled a swallowable, wireless capsule designed to emit light inside the gut, allowing nerve cells to be activated without surgery—a development poised to transform gastrointestinal research and therapy.

The capsule, known as ICOPS, represents a remarkable leap in non‑invasive bioengineering. It employs optogenetic technology, by which specific neurons are genetically modified to respond to light. Once the target cells become light‑sensitive, patients can ingest an LED‑equipped capsule that, when powered externally, delivers precise stimulation to regions of the gut. This allows researchers to observe and influence neuronal circuits involved in digestion with a level of control previously limited to invasive approaches.

ICOPS stands out for its battery‑free design. It receives power wirelessly via magnetic induction from an external transmitter, enabling a compact, rodent‑scale form factor suitable for testing in freely moving animals. Crafted entirely via in‑house 3D printing—micro‑LEDs and custom coils included—this capsule avoids more expensive and restrictive cleanroom fabrication techniques.

Early animal trials suggest ICOPS can target neural circuits governing critical physiological functions, offering potential new avenues for treating gut motility disorders such as gastroparesis, where the stomach fails to empty properly. Simultaneously, the ability to stimulate region‑specific neural activity may trigger metabolic and hormonal responses, hinting at applications in metabolic disease and eating disorder therapies.

ICOPS is part of a broader research portfolio pioneered by Ramadi. Earlier innovations include FLASH, an electroceutical capsule that delivers electrical stimulation to modulate hunger‑related hormones, and IMAG, which uses magnetic fields to track pill location through the gut.

Adoption of ICOPS could revolutionise how scientists study the gut’s ‘second brain’—a vast, complex neural network fundamental to bodily control but historically difficult to study in its natural state owing to the invasive nature of previous optogenetic techniques.

Materials innovation plays a central role in this advancement. By eliminating the battery and using magnetic induction, the capsule remains small and unobtrusive. Its 3D‑printed construction offers scalability, making further adaptation for varied experimental models feasible.

Looking ahead, the implications for human healthcare are significant. The precision offered by ICOPS could enable therapies targeting select neural circuits within the gut, offering fine‑tuned interventions far more sophisticated than current broad‑spectrum prokinetic or antikinetic drugs. Furthermore, the platform may evolve to provide electrical stimulation or even deliver drugs directly to targeted gut regions.

That said, the path to clinical use remains lengthy. At present, ICOPS has demonstrated efficacy in rodent models. Transition to human clinical trials may take a decade or more, as researchers must navigate regulatory approval, safety testing, and scalability concerns.

Still, the research has drawn attention across scientific and media outlets, from Gulf News dubbing it a “Light Pill” capable of unlocking gut‑brain secrets to technical summaries highlighting how light‑activated capsules are revolutionising understanding of gut‑brain interactions.

Behind the innovation is a multi‑disciplinary team including Mohammed Elsherif, Rawan Badr El‑Din, Zhansaya Makhambetova, Heba Naser, Rahul Singh, Keonghwan Oh, Revathi Sukesan, Maylis Boitet, and Sohmyung Ha, working together across divisions at NYU Abu Dhabi and NYU Tandon. The project has benefited from funding awarded by NYU Abu Dhabi and Tamkeen through the CENTMED research centre.